Evidence map›Paper›PMID 34580591›Full record

ArticleJournal of oncology2021

Research on Effectiveness of Prior Cancer on Survival Outcomes for Patients with Nonmetastatic Triple-Negative Breast Cancer: A Competing Risk Analysis and Propensity Score Matching Analysis of the SEER Database.

Heyan Chen, Lutong Yan, Shengyu Pu, Lizhe Zhu, Huimin Zhang, Can Zhou

Abstract read
In one paragraph

Article in Journal of oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Heyan ChenDepartment of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.ORCID https://orcid.org/0000-0002-6642-8435
Lutong YanDepartment of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.ORCID https://orcid.org/0000-0002-6398-8269
Shengyu PuDepartment of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.ORCID https://orcid.org/0000-0002-8121-4507
Lizhe ZhuDepartment of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.ORCID https://orcid.org/0000-0002-5507-6323
Huimin ZhangDepartment of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.ORCID https://orcid.org/0000-0003-2636-7858
Can ZhouDepartment of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.ORCID https://orcid.org/0000-0003-3885-9702

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionKnowledge of the effect of prior cancer on long-term survival outcomes for patients with nonmetastatic triple-negative breast cancer (TNBC) remained unclear. The aim of this study was to explore and identify the effectiveness of prior cancer on breast cancer-specific death (BCSD) and other cause-specific death (OCSD) in patients with nonmetastatic TNBC. MATERIALS AND

methodsData of 29,594 participants with nonmetastatic TNBC patients were extracted from the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2016. Prognostic predictors were identified by propensity score matching (PSM) analysis combined with univariate cumulative incidence function (CIF) and multivariate Fine and Gray competitive risk analyses.

resultsAmong the women with nonmetastatic TNBC included in the unmatched cohort, a total of 5,375 (18.2%) subjects had prior cancers (P-TNBC) and 24,219 (81.8%) had no prior cancer (NP-TNBC). Patients with P-TNBC tended to have poorer BCSD (Gray's test,

conclusionOur study demonstrated that prior cancer was related to the worse BCSD and OCSD rate and could be identified as a reliable survival predictor for patients with nonmetastatic TNBC. This study may provide some reference value for the treatment mode of TNBC patients with prior cancer in the future.

Identifiers

PMID34580591
PMCPMC8464407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.